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ABSTRACT 
Background: Many studies have shown that transforming rowth factor 
(TGF)-[3 has a major ole in renal scarring in many renal diseases and hypertension. 
Objectives: The primary aim of this study was to investigate both the rela- 
tionship between hypertension a d serum and urinary levels of TGF-[32 (a more 
sensitive isoform for glomeruli than TGF-131), and the effects of combination 
therapy with perindopril + indapamide on microalbuminuria, which becomes 
an early indicator of hypertensive b nign nephropathy, and serum and urinary 
TGF-~2 levels in patients with mild to moderate essential hypertension. I  addi- 
tion, we examined the possible relationship between TGF-fl2 gene polymorph- 
ism and essential hypertension. 
Methods: This study was conducted at the Department of Nephrology, 
Medical Faculty, Gazi University, Ankara, Turkey. Patients aged ~18 years with 
newly diagnosed mild to moderate ssential hypertension (systolic/diastolic 
blood pressure [SBP/DBP] >120/>80 mm Fig) who had not previously received 
antihypertensive tr atment were included in the study. Patients with stage I
hypertension received perindopril 2 mg + indapamide 0.625 mg (tablet), and 
patients with stage II hypertension received perindopril 4 mg + indapamide 
1.125 mg (tablet). All study drugs were given OD (morning) PO with food for 
6 months. Serum and urinary TGF-~2 and creatinine l vels and serum and urin- 
ary albumin levels were measured before and after perindopril + indapamide 
administration. Amplified DNA fragments of the TGF-~2 primer region were 
screened using amplification refractory mutation system polymerase chain 
reaction analysis, and the number of ACA repeats was confirmed by DNA 
sequencing. Genetic studies were performed using a commercial TGF-~2 kit. 
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Results: Forty patients were enrolled in the study, and 38 patients (27 wom- 
en, 11 men; mean [SD] age, 46.3 [6.5] years) completed it. SBP and DBP were 
significantly decreased from baseline with perindopril/indapamide (both, P < 
0.001). Microalbuminuria and urinary TGF-[52 levels also decreased significantly 
from baseline (P = 0.04 and P < 0.001, respectively), whereas the serum TGF-~2 
level did not change significantly. Three patients, all of whom were found to 
have TGF-fi2 gene mutations, had increased urinary TGF-[52 levels despite good 
blood pressure control. 
Conclusions: The results of this study in patients with mild to moderate 
hypertension suggest that, despite good clinical control of blood pressure, the 
persistence of microalbuminuria and high urinary TGF-~2 levels might predict 
renal impairment. When treating these patients, genetic tendencies and possi- 
ble polymorphisms on the TGF-fi2 locus should be kept in mind. (Curt Ther Res 
Clin Exp. 2005;66:266-278) Copyright © 2005 Excerpta Medica, Inc. 
Key words: hypertension, perindopril, indapamide, microalbuminuria, TGF-[52, 
gene polymorphism. 
INTRODUCTION 
Rapid deterioration of renal function and other renal abnormalities (eg, fibrin- 
oid and necrotizing changes in parenchymal nd vascular structures) are seen 
in some patients with uncontrolled hypertension) Renal lesions associated 
with benign hypertension have been termed benign nephrosclerosis. 2 
Microalbuminuria becomes an important clinical indicator of renal damage in 
patients with hypertension. 3 However, it is a weak predictor of renal disease pro- 
gression in nondiabetic patients with hypertension. I  fact, aggressive control of 
hypertension is required in the presence of albuminuria. 4,5Even though microal- 
buminuria can be helpful in predicting renal disease, more evidence is needed 
for the assessment of hypertensive b nign nephrosclerosis in predicting renal 
disease. 
Some growth factors might play a role in the progression of renal scarring in 
hypertensive patients. Two studies 6,7 have suggested that transforming growth 
factor (TGF)-[3 has a significant role in renal scarring in different renal diseases 
and hypertension. Thus, either serum or urinary TGF-~ levels might reflect he 
progression ofthis scarring. Although both the TGF-[31 and TGF-~2 isoforms are 
expressed throughout the kidney, TGF-[32 and its mRNA are found mainly in the 
glomeruli. 8 A study of antibodies against 3 isoforms 9 showed that TGF-~I and 
TGF-[33 were present in the tubule cells, whereas taining for TGF-[32 was intense 
in the glomeruli and faint in the tubules. Several previous studies 1°-12 have 
reported a strong correlation between TGF-fll DNA polymorphisms, hyperten- 
sion, and hypertension-related en -organ damage. 
Because of generally inadequate compliance with dietary sodium restriction 
in the Turkish population, physicians tend to begin antihypertensive tr atment 
with a low-dose diuretic/antihypertensive combination) 3,14 
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The primary aim of this study was to investigate the relationship between 
hypertension a d serum and urinary levels of TGF-[52 (a more sensitive isoform 
for glomeruli compared with TGF-~I ), and the effects of combination therapy 
with the angiotensin-converting e zyme inhibitor perindopril plus the diuret- 
ic indapamide on microalbuminuria and serum and urinary TGF-~2 levels in 
patients with mild to moderate ssential hypertension. I  addition, we exam- 
ined the possible relationship between TGF-fi2 gene polymorphism and essen- 
tial hypertension. 
PATIENTS AND METHODS 
This study was conducted at the Department of Nephrology, Medical Faculty, 
Gazi University, Ankara, Turkey. The study protocol was approved by the ethics 
committee at the university (Gazi University Medical Faculty) retrospectively, 
because that committee was not formed until after the study was completed. 
Inclusion and Exclusion Criteria 
Turkish patients aged a18 years with newly diagnosed mild to moderate essen- 
tial hypertension (systolic/diastolic blood pressure [SBP/DBP] >120/>80 mm Hg) 
who were seen in an outpatient clinic were recruited for the study. The authors 
believe these patients were representative of the general Turkish population in 
terms of socioeconomic and cultural status. 
Exclusion criteria included the presence of secondary hypertension (renal 
failure, rheumatoid diseases, pregnancy, endocrine causes) or diabetes mellitus 
or a history of the use of any antihypertensive drug or any other drug that might 
affect renal function. 
All patients were informed of the study design and provided written in- 
formed consent to participate. 
Measurements 
To rule out secondary hypertension at screening, routine blood biochemis- 
try tests (including fasting plasma glucose [FPG] level, blood urea nitrogen 
[BUN] level, and serum concentrations of creatinine [SCC], total cholesterol 
[TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cho- 
lesterol [LDL-C], very-low-density lipoprotein cholesterol, triglycerides [TG], 
total protein, albumin, uric acid, sodium, potassium, calcium, and phosphorus), 
urinalysis, thyroid function tests, creatinine clearance (CrCI), chest radiogra- 
phy, electrocardiography, andabdominal ultrasonography were performed. Se- 
rum albumin and serum and urinary TGF-~2 levels were measured. To measure 
TGF-[52 levels, pretreatment 24-hour urine and blood samples were collected 
and stored at -70°C, according to kit recommendations (Human TGF-beta 2 
DuoSet Economy Pack, 45 Plate, Quantikine, R&D Systems, Inc., Minneapolis, 
Minnesota). Possible correlations between microalbuminuria and basic study 
parameters (SBP/DBP and BUN, SCC, and serum and urinary TGF-[52) were inves- 
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tigated. The presence of microalbuminuria was assessed using nephelometry 
(Turbox lmmunochemistry S stem, Orion Diagnostica, Espoo, Finland). Values 
>16.6 mg/L were considered as microalbuminuria. 
For all patients, blood pressure was measured in both arms in the sitting and 
supine positions using a standard hand-grip sphygmomanometer after at least 
15 minutes of rest. The mean of 3 measurements was used. 
Staging of hypertension was determined based on the recommendations in 
the Sixth Report of the Joint National Committee. 15 Patients were instructed to 
return to the outpatient clinic for monthly follow-up for 6 months. Follow-up 
consisted of a history of patient observations (eg, efficacy, adverse effects 
[AEs]); physical examination, including blood pressure measurements; and 
blood biochemistry. Patients with high serum lipid levels (TC >200 mg/dL or 
TG >200 mg/dL) were initially treated with atorvastatin 10 mg PO QD (evening). 
Patients with stage I hypertension received perindopril 2 mg + indapamide 
0.625 mg (tablet), and patients with stage II hypertension received perindopril 
4 mg + indapamide 1.125 mg (tablet). All study drugs were given QD (morning) 
PO with food for 6 months. Patients with stage I hypertension whose blood 
pressure had not normalized were switched to the higher dose of perindopril + 
indapamide. 
At the end of the 6-month treatment period, all of the assessments were re- 
peated and 24-hour urine and blood samples were again collected to measure 
TGF-[32 levels. Samples were thawed at room temperature and assessed using an 
enzyme-linked immunosorbent assay kit (Quantikine Human TGF-[32 Immuno- 
assay, R&D Systems, Inc.). 
Genetic studies were performed using a commercial TGF-~2 kit (R&D Sys- 
tems, Inc.) human polymerase chain reaction (PCR) TGF-~2 primer pair (catalog 
number RDP-27). First, DNA was extracted from peripheral blood (5 mL collect- 
ed into EDTA) by the standard method, with proteinase K digestion followed 
by phenol/chloroform extraction. The TGF-[32 primer region was as follows: 
5'-CGA CGA CAA CGA TGA TGC TT-3' and 5'-TAC GTA CAG CAA CAA CTC CAC TT-3'. 
Amplified DNA fragments of the TGF-~2 primer region were screened by ampli- 
fication refractory mutation system-PCR analysis, and the number of ACA 
repeats was confirmed using DNA sequencing. Alleles 1, 2, and 3 of the gene 
contained 7, 8, and 9 ACA repeats, respectively. The TGF-fl2 gene had an ACA 
repeat sequence in its 3'-noncoding region, and polymorphisms were depen- 
dent on differences in ACA repeats. 16 PCR amplification was carried out in 50-pL 
volumes of reaction mixtures containing 75 mM tris-hydrochloride (pH 8.8), 
200 mM (NH4) 2SO 4, 0.1% Tween-20, 2.0 mM MgCI 2, 50 mM of each deoxyribonu- 
cleotide triphosphate, 50 mM of previously reported 1~ specific primers, 1 U Taq 
DNA polymerase (Promega Corporation, Madison, Wisconsin), and a 0.2- to 
0.5-mg DNA sample. All PCR reactions were processed at 94°C for 4 minutes, fol- 
lowed by 30 cycles at 94°C for 45 seconds, 55°C for 45 seconds, and 72°C for 
45 seconds; the final extension at 72°C for 10 minutes was performed in an auto- 
mated thermal cycler (Perkin Elmer Cetus 9600, Applied Biosystems, Foster City, 
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California). The amplified products were analyzed using electrophoresis on 1.5% 
agarose gel. 
Tolerability was assessed using patient interview. 
Statistical Analysis 
Descriptive statistics are expressed as mean (SD) for parametric data or 
median (range) for nonparametric data. The Student test and Wilcoxon signed 
rank test were used to compare means of groups. Correlations were evaluated 
using the Pearson and Spearman bivariate correlation tests. The Kruskal-Wallis 
test was used to analyze between-group differences. P < 0.05 was considered sta- 
tistically significant. 
RESULTS 
Forty patients entered the study, and 2 of them dropped out (1 moved to anoth- 
er city and 1 was lost to follow-up). Thirty-eight patients (27 women, 11 men; 
mean [SD] age, 46.3 [6.5] years) completed the study (Table I). At baseline, 
mean (SD) SBP/DBP was 165.1 (8.1)/103.4 (6.6) mm Hg. Eight of 38 patients 
had stage I hypertension and were treated with perindopril 2 mg + indapamide 
0.625 mg/d, and 30 had stage II hypertension and were treated with perindopril 
4 mg + indapamide 1.25 mg/d. By the end of the first month of treatment, 
2 patients with stage I hypertension were switched to the higher dose of 
perindopril + indapamide because their blood pressure had not normalized. 
Table I. Baseline demographic and clinical characteristics of the 
study group (N -- 38). 
Characteristic Value 
Demographic 
Age, mean (SD), y 46.3 (6..5) 
Sex, no. 
Female 27 
Male I I  
Clinical 
Body mass index, mean, kg/m 2 27.1 
Concomitant medications, no. 
Cholesterol lowering 14 
Hypertension stage, no. 
I* 8 
II t 30 
*These patients were assigned to receive perindopril 2 rng + indaparnide 
0.625 rag. 
tThese patients were assigned to receive perindopril 4 rng + indaparnide 
1.25 rag. 
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Fourteen patients received atorvastatin during the study for the treatment of 
hyperlipidemia. 
Clinical findings and biochemical parameters at baseline and after 6 months 
of treatment are shown in Table II. After 6 months of antihypertensive therapy, 
mean SBP/DBP was significantly reduced from baseline (change, 42.4/19.8 mm Hg, 
respectively; both, P < 0.001). Significant decreases from baseline were seen in 
microalbuminuria (median [range], 6 [1-150] vs 5 [1--42] mg/L; P = 0.04) and 
urinary TGF-[52 level (median [range], 16.4 [0.87-204.5] vs 6.3 [0.87-21.9] pg/mL; 
P < 0.001), whereas the change in serum TGF-~2 level was not significant (medi- 
an [range], 32.8 [1.9-294.6] vs 1.9 [1.9-255.0] pg/mL). 
When the data for each patient were examined individually, we found that 
urinary TGF-fi2 levels were decreased in 31 patients, increased in 3 patients, 
and did not change significantly in 4 patients, despite good blood pressure 
control. 
At baseline and after 6 months of treatment, SBP/DBP and serum TGF-[52, BUN, 
and SCC did not correlate with the presence of microalbuminuria. However, a 
Table II. Comparison of blood pressure and biochemical concentrations before and 
after 6 months of treatment with perindopril + indapamide for mild to mod- 
erate essential hypertension. Values are presented as mean (SD) unless oth- 
erwise specified. 
Parameter Before Treatment After Treatment P* 
SBP, mm Hg 165.1 (8.1) 1 22.7 (7.0) <0.001 
DBP, mm Hg 103.4 (6.6) 83.6 (3.7) <0.001 
FPG, mg/dL 102.6 (11.7) 99.0 (9.8) 0.03 
BUN, mg/dL 14.6 (3.8) 15.6 (3.5) NS 
SCC, mg/dL 0.9 (0.1) 0.9 (0.1) NS 
TC, mg/dL 221.2 (36.6) 205.0 (35.6) 0.002 
HDL-C, mg/dL 43.0 (10.9) 48.0 (12.6) 0.003 
LDL-C, mg/dL 144.4 (33.6) 1 32.5 (47.3) NS 
CrCI, mL/min 98.4 (24.1) 1 02.6 (23.4) NS 
Microalbuminuria, mg/L t 6.0 (1-150) 5.0 (1-42) 0.04 
Serum TGF-132, pg/mL t 32.8 (1.9-294.6) 1.9 (1.9-255.0) NS~ 
Urinary TGF-132, pg/mL t 16.4 (0.87-204.5) 6.3 (0.87-21.9) <0.001 
SBP = systolic blood pressure; DBP = diastolic blood pressure; FPG = fasting plasma glucose; BUN = 
blood urea nitrogen; NS = nonsignificant; SCC = serum creatinine concentration; TC = total choles- 
terol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; 
CrCI = creatinine clearance; TGF-132 = transforming rowth factor-132. 
*Student t test unless otherwise specified. 
tBecause of nonparametric distribution, values are presented as median (range). 
~Wilcoxon signed rank test. 
271 
CURRENT THERAPEUTIC RESEARCH 
strong correlation was found between the presence of microalbuminuria and uri- 
nary TGF-[52 level at baseline (Spearman correlation [rs] = 0.650; P = 0.001) and 
after 6 months of treatment (r s = 0.711; P = 0.001) (Table III). 
When laboratory parameters were analyzed based on the presence of micro- 
albuminuria, no significant between-group differences were found (Table IV). 
When DNA analysis was performed on individual samples, the samples of 3 
patients howed TGF-fi2 gene polymorphism. These primers amplified between 
Arg 299 and Arg of the 433 of the unprocessed 442 aa form of the TGF-~2 protein. 
The aa encoded by the primers was identical to the sequence of the TGF-fl2 gene 
available in the public domain (accession umber M19154). Allele 2 of the TGF-fi2 
gene, corresponding to 8 ACA repeats, was common between these 3 patients. 
None of the patients complained of treatment-emergent AEs (cough, head- 
ache, peripheral vertigo, hyperkalemia, or asthenia) that required changing the 
treatment protocol. Four (10.5%) patients reported nausea during the first 3 
weeks of treatment, but this effect was mild and transient. 
DISCUSSION 
In many diseases of the kidneys, the progression to end-stage renal disease 
(ESRD) depends largely on the severity of the damage to both the tubulointer- 
stitial and glomerular compartments. Extensive reduction of renal mass is one 
of several factors that induce glomerulosclerosis. 17 
Because compliance with a salt-restricted iet is often inadequate in the 
Turkish population, physicians tend to begin antihypertensive treatment with 
low-dose combination diuretic therapy. 13,14 We treated hypertension with a com- 
bination of perindopril + indapamide because of its well-known effectiveness 
Table III. Correlat ion between microa lbuminur ia  and other  parameters 
before and after 6 months  of t reatment  w i th  per indopr i l  + in- 
dapamide for  mild to moderate essential hypertension (N = 38). 
Before Treatment After Treatment 
Pa~meter ~* P ~* P 
SBP -0.120 NS 0.190 NS 
DBP -0.020 NS 0.010 NS 
BUN -0.088 NS 0.090 NS 
SCC 0.00S NS -0.007 NS 
Serum TG F-132 0.022 NS 0.247 NS 
Urinary TGF-132 0.650 0.001 0.711 0.001 
r~ = Spearman correlation coefficient; SBP = systolic blood pressure; NS = nonsignificant; 
DBP = diastolic blood pressure; BUN = blood urea nitrogen; SCC = serum creatinine con- 
centration; TGF-[32 = transforming rowth factor-J32. 
*Because of nonparametric distribution, Spearman correlation was performed. 
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in decreasing intraglomerular pressure. Is We used indapamide because hydro- 
chlorothiazide promotes growth of vascular smooth muscle. 19 
A significant decrease in blood pressure was achieved by the end of the 
6-month treatment period (P < 0.001). At the end of the study, FPG level had 
decreased statistically significantly (P = 0.03) (although the decrease was not 
clinically meaningful), whereas the TC level decreased (P = 0.002) and the HDL-C 
level increased (P = 0.003), suggesting that the patients conformed to the rec- 
ommendations of cholesterol-lowering treatment, diet, and exercise. 
Impaired renal function is one of the most important and well-known conse- 
quences of uncontrolled hypertension. Angiotensin-converting e zyme inhibi- 
tion causes vasodilation of efferent arterioles and may cause defects in renal 
perfusion, particularly in patients with conditions uch as congestive heart fail- 
ure, renal arterial stenosis, and hypovolemia. 2° Although none of the patients in 
the present study had complicated hypertension, we did not find any decrease 
in renal function based on SCC or CrCI at baseline or at the end of the study 
period. 
Pathogenetic pathways common to both benign nephrosclerosis and micro- 
albuminuria might suggest hat microalbuminuria plays a role in the develop- 
ment of hypertensive benign nephropathy. 5 Although microalbuminuria h s 
been attributed to various mechanisms (ie, functional and/or structural abnor- 
malities of the glomeruli, vessels, and tubuli), the origin of hypertensive 
microalbuminuria remains obscure. 17 Bigazzi et aP and Tsioufis et a121 showed 
that microalbuminuria is closely related to impaired arterial elasticity in un- 
treated patients with essential hypertension. The same studies also showed 
a significant decrease in CrCI, particularly during the first 6-month follow-up in 
the microalbuminuric group. It could be speculated that controlling microalbu- 
minuria might delay the progression of hypertension-related r nal disease for a 
longer period compared with controlling blood pressure alone. 
In the present study, 6 (15.8%) patients had microalbuminuria at baseline; 5
(83.3%) of them had normal albumin levels at the end of the 6-month treatment 
period. No correlation was found between the presence of microalbuminuria 
and hypertension staging. This finding suggests that microalbuminuria is not 
only affected by systemic blood pressure but also by activation of the renin- 
angiotensin-aldosterone system and increased intraglomerular p essure. IT We 
observed a reduction in microalbuminuria as well as good blood pressure con- 
trol. However, it is uncertain whether this effect would have been achieved with 
only the combination ofperindopril + indapamide or if it was the effect of treat- 
ment with an angiotensin-converting e zyme inhibitor. To answer this question, 
further research of similar design but using other antihypertensive agents 
should be performed. 
Inducing cell growth is only one of the multiple effects that TGF-~ exerts on 
cells. TGF-~ has also been shown to mediate mesangial sclerosis after experi- 
mental acute glomerulonephritis and will likely be shown to be important in a 
variety of other renal disorders as well. 9-11 
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Five TGF-~ isoforms share 64% to 82% homology among their amino acid 
sequencesJ  ° TGF-~I is widely distributed in renal tissue, with immunohisto- 
chemical staining showing the greatest concentration of TGF-~I protein in the 
tubular epithelial cells. With the use of antibodies against each of 3 isoforms, 
TGF-[51 and TGF-[53 have been identified in the tubule cells, whereas TGF-[52 stain- 
ing was shown to be most intense in the glomeruli. 1°,22,23 
Although the role of TGF-~I has been investigated extensively in hyperten- 
sive patients 24-2G with ESRD, a literature search (key words: TGF-fl2, renal scar- 
ring, hypertension, and microalbuminuria; years: 1985-2004) did not identify any 
studies of TGF-~2 in these patients. Yu et a127 assessed the fibrogenic role of 
TGF-[52 on renal cells, particularly in glomeruli. They found that each isoform 
increased matrix protein synthesis and reduced matrix degradation by renal 
cells similarly, and that TGF-~2 stimulated TGF-~I production. 
In our study, serum TGF-[52 levels varied widely (range, 1.9-294.6 pg/mL) and 
were not correlated with blood pressure levels. Also, no correlation was found 
between serum TGF-[32 levels and microalbuminuria, which becomes an early 
indicator of hypertensive benign nephrosclerosis. All TGF-[5 isoforms are wide- 
ly distributed in tissues other than the kidney, and the serum levels of the iso- 
forms may be affected not only by renal abnormalities but also other patholog- 
ic processes, such as atherosclerosis. For this reason, serum levels of TGF-~2 
might not specifically reflect renal damage. 
Several trials ~,24,2~,29 have shown that urinary cytokine level is a more effec- 
tive indicator of renal disease progression compared with serum cytokine level. 
In fact, circulating cytokines might originate outside of the kidneys, and the 
glomerular filtration rate of these molecules is still unclear. Because cytokines 
that have a crucial role in the progression of renal fibrosis might be expressed 
in renal tissue, measuring urinary levels of these molecules might be essential 
in evaluating the progression of nephrosclerosis. 3°,31 
In the patients with microalbuminuria (6/38), the high levels of urinary TGF-~2 
at the beginning of the study (median, 37.5 pg/mL [range, 15.5-170.8 pg/mL]) 
decreased significantly by the end of the study (median, 6.4 pg/mL [range, 
1.9-19.2 pg/mL]; P = 0.02), as did SBP/DBP (both, P < 0.001). Urinary TGF-~2 lev- 
els were well correlated with microalbuminuria atthe beginning and end of the 
study. These findings were similar to results of previous trials that showed uri- 
nary cytokine level to be an early and accurate indicator of renal disease, as 
was microalbuminuria. 23,29 These data suggest that control of microalbuminuria 
might delay the progression of hypertension-related r nal disease and that uri- 
nary TGF-~2 level and microalbuminuria might be good markers as well. When 
we analyzed the data according to existing microalbuminuria, results did not 
show a significant between-group difference. This finding might suggest hat 
urinary TGF-~2 levels should be examined independent of microalbuminuria n 
hypertensive patients to detect renal impairment. 
Previous studies 16,23 showed multiple polymorphisms for 3 isoforms of the 
TGF-fl gene. Freedman et a132 found that TGF-~2 gene polymorphism did not 
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seem to play a major role in the initiation of renal failure in African Americans. 
However, Alansari et a133 defined 2 novel polymorphisms in the TGF-fl2 gene in 
3 white populations in Spain, Turkey, and the United Kingdom that may play a 
role in diseases associated with the TGF-fi2 gene. Although we had a small num- 
ber of patients for a genetic trial, we also tried to determine whether a relation- 
ship exists between TGF-fl2 gene polymorphism and urinary and serum TGF-[$ 2 
levels. Interestingly, 3 patients with increased urinary TGF-[32 levels despite 
good blood pressure control and decreased microalbuminuria also had the only 
3 TGF-fl2 gene mutations we found. If the number of patients in the study had 
been higher, the probability of having samples with mutated genes would have 
been greater and we could have speculated that these mutations would be pre- 
dictive of renal disease progression, even in patients with decreased blood 
pressure and microalbuminuria. Certainly, these 3 samples are not sufficient 
proof of the genetic tendency of benign nephrosclerosis in our study popula- 
tion. Further esearch using a large number of patients with hypertensive r nal 
disease is necessary. 
This study was planned as a self-controlled trial; the findings would have been 
more useful if we had also included patients with another condition (eg, diabetes) 
or a control group for comparison. Another limitation of this study was the 
necessity of combination treatment. Certainly, we cannot state that the im- 
provement seen in the patients during the study was the result of the treatment 
modality. 
CONCLUSIONS 
The results of this study in patients with mild to moderate essential hypertension 
suggest that, despite good clinical control of blood pressure in these patients, the 
persistence of microalbuminuria and high urinary TGF-[32 levels might predict 
renal impairment. When treating these patients, genetic tendencies and possible 
polymorphisms on the TGF-fl2 locus should be kept in mind. 
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